Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation

A. Primary Aim To determine the safety and efficacy of tafamidis in patients who have undergone heart or combined heart/liver transplantation for ATTR (wild-type or variant) cardiac amyloidosis. Primary Hypothesis. Initiation of the TTR stabilizer, tafamidis, post heart or heart/liver transplant for ATTR cardiac amyloidosis, (wild-type or variant disease) will be associated with an increase in plasma transthyretin levels during 12 months of therapy. B. Secondary Aims 1. To determine the impact of tafamidis on serial questionnaire assessments that quantitate and determine the severity and clinical implications of motor, sensory, and autonomic neurologic impairment in participants over 12 months with cardiac transplantation. 2. To determine the impact of tafamidis on serial questionnaire assessment of activity and social participation limitation, dysautonomia and nutritional status in participants over 12 months with cardiac transplantation. 3. To determine the impact of tafamidis on transplantation-related adverse events in participants over 12 months with cardiac transplantation. 4. To establish the pharmacokinetics of tafamidis in participants with cardiac transplantation over 12 months. C. Study Type / Design The proposed study will be a single-arm, intervention clinical trial. Because of the observed efficacy of tafamidis and other therapies for both ATTRv and ATTRwt, there is no clinical equipoise for an inactive-comparator placebo arm. D. Expected Outcomes Upon completion of this clinical trial, it is our expectation that we will establish the efficacy and safety of tafamidis in patients with who have undergone heart transplantation for ATTR-CA. Further, we expect to have shown that tafamidis will have predictable pharmacokinetics and will lead to improvement in polyneuropathy questionnaire scores and mBMI. Such findings would be important, because they would justify the use of tafamidis to halt ATTR progression in patients who have undergone heart transplantation for advanced ATTR-CA. Specifically, we will expect the following: 1. Tafamidis will be safe and well tolerated in the post heart transplant population, providing data to support its use as a therapeutic agent to halt the progression of extra cardiac manifestations of TTR amyloidosis post HT for end stage ATTR-CA. 2. TTR levels will increase from baseline at the 3-month visit and remain stable throughout the remainder of the study period. This increase in serum TTR will be comparable to that seen in the ATTR-ACT trial, reflective of stabilization of TTR and treatment efficacy in this patient population. 3. Serial assessment of Norfolk-QoL-DN, COMPASS-31 and R-ODS questionnaires will demonstrate stable disease at 12 months as measured by autonomic symptoms and quality of life. 4. There will be no increase, from baseline, in incidence of treated acute cellular rejection, antibody mediated rejection, active CMV infection, coronary allograft vasculopathy or post-transplant lymphoproliferative disorder as a result of concurrent TTR stabilizing therapy with tafamidis. 5. Plasma pharmacokinetics of tafamidis free acid in the post HT population will be similar to those observed in previous studies of healthy volunteers.